The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Irinotecan: 25 years of cancer treatment
Abstract
Twenty-five years ago, the cytotoxic drug irinotecan (IRT) was first approved in Japan for the treatment of cancer. For more than two decades, the IRT prodrug has largely contributed to the treatment of solid tumors worldwide. Nowadays, this camptothecin derivative targeting topoisomerase 1 remains largely used in combination regimen, like FOLFIRI and FOLFIRINOX, to treat metastatic or advanced solid tumors, such as colon, gastric and pancreatic cancers and others. This review highlights recent discoveries in the field of IRT and its derivatives, including analogues of the active metabolite SN38 (such as FL118), the recently approved liposomal form Nal-IRI and SN38-based immuno-conjugates currently in development (such as sacituzumab govitecan). New information about the IRT mechanism of action are presented, including the discovery of a new protein target, the single-stranded DNA-binding protein FUBP1. Significant progress has been made also to better understand and manage the main limiting toxicities of IRT, chiefly neutropenia and diarrhea. The role of drug-induced inflammation and dysbiosis is underlined and strategies to limit the intestinal toxicity of IRT are discussed (use of β-glucuronidase inhibitors, plant extracts, probiotics). The detailed knowledge of the metabolism of IRT has enabled the identification of potential biomarkers to guide patient selection and to limit drug-induced toxicities, but no robust IRT-specific therapeutic biomarker has been approved yet. IRT is a versatile chemotherapeutic agent which combines well with a variety of anticancer drugs. It offers a large range of drug combinations with cytotoxic agents, targeted products and immuno-active biotherapeutics, to treat a variety of advanced solid carcinoma, sarcoma and cancers with progressive central nervous system diseases. A quarter of century after its first launch, IRT remains an essential anticancer drug, largely prescribed, useful to many patients and scientifically inspiring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 702
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.
Wall, M. E., & Wani, M. C. (1995) · PubMed · Cited by 376
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
NCCN Guidelines Updates: Pancreatic Cancer.
Tempero, M. A. (2019) · PubMed · doi:10.6004/jnccn.2019.5007 · Cited by 322
Li, F., Jiang, T., Li, Q., & Ling, X. (2017) · PubMed · Cited by 315
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
Guidance on the management of diarrhoea during cancer chemotherapy
Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., Wedlake, L., Bridgewater, J., Glynne-Jones, R., Allum, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70006-3 · Cited by 257
Mego, M., Chovanec, J., Vochyanova-Andrezalova, I., Konkolovsky, P., Mikulova, M., Reckova, M., Miskovska, V., Bystricky, B., Beniak, J., Medvecova, L., et al. (2015) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2015.03.008 · Cited by 236
Shitara, K., Iwata, H., Takahashi, S., Tamura, K., Park, H., Modi, S., Tsurutani, J., Kadowaki, S., Yamaguchi, K., Iwasa, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30088-9 · Cited by 232
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update
Khorana, A. A., McKernin, S. E., Berlin, J., Hong, T. S., Maitra, A., Moravek, C., Mumber, M., Schulick, R., Zeh, H. J., & Katz, M. H. G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00946 · Cited by 206
Takegawa, N., Nonagase, Y., Yonesaka, K., Sakai, K., Maenishi, O., Ogitani, Y., Tamura, T., Nishio, K., Nakagawa, K., & Tsurutani, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30870 · Cited by 196
Lian, Q., Xu, J., Yan, S., Huang, M., Ding, H., Sun, X., Bi, A., Ding, J., Sun, B., & Geng, M. (2017) · Cell Research · doi:10.1038/cr.2017.54 · Cited by 190
Goldenberg, D. M., & Sharkey, R. M. (2019) · mAbs · doi:10.1080/19420862.2019.1632115 · Cited by 164
Mori, K., Kondo, T., Kamiyama, Y., Kano, Y., & Tominaga, K. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0585-0 · Cited by 157
Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Ashton, K., Yeoh, A. S. J., Al‐Dasooqi, N., & Keefe, D. M. K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00671.x · Cited by 156
Sanghani, S. P., Quinney, S. K., Fredenburg, T. B., Davis, W. I., Murry, D. J., & BOSRON, W. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.505 · Cited by 145
Wardill, H. R., Gibson, R. J., Sebille, Y. Z. A. V., Secombe, K. R., Coller, J. K., White, I. A., Manavis, J., Hutchinson, M. R., Staikopoulos, V., Logan, R. M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0990 · Cited by 143
Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity
Roberts, A. B., Wallace, B. D., Venkatesh, M. K., Mani, S., & Redinbo, M. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.085852 · Cited by 140
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Weiss, G. J., Waypa, J., Blaydorn, L., Coats, J., McGahey, K., Sangal, A., Niu, J., Lynch, C. A., Farley, J. H., & Khemka, V. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.145 · Cited by 135
Dotan, E., Cohen, S. J., Starodub, A., Lieu, C. H., Messersmith, W. A., Simpson, P. S., Guarino, M. J., Marshall, J. L., Goldberg, R. M., Hecht, J. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9011 · Cited by 134
Liu, X., Jiang, J., Chan, R., Ji, Y. C., Lu, J., Liao, Y., Okene, M. O., Lin, J., Lin, P. K., Chang, C. H., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06164 · Cited by 128
Chamseddine, A. N., Ducreux, M. P., Armand, J., Paolettí, X., Satar, T., Paci, A., & Mir, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.002 · Cited by 124
Management of recurrent Ewing sarcoma: challenges and approaches
Mater, D. V., & Wagner, L. M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s170585 · Cited by 119
Capello, M., Lee, M., Wang, H., Babel, I., Katz, M. H. G., Fleming, J. B., Maitra, A., Wang, H., Tian, W., Taguchi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv132 · Cited by 111
Hutchinson, M. R., Loram, L. C., Zhang, Y., Shridhar, M., Rezvani, N., Berkelhammer, D. L., Phipps, S., Foster, P. S., Landgraf, K., Falke, J. J., et al. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.03.067 · Cited by 110
Cheng, K.-W., Tseng, C.-H., Tzeng, C., Leu, Y.-L., Cheng, T.-C., Wang, J., Chang, J., Lu, Y., Cheng, C. C., Chen, I., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.029 · Cited by 107
Soe, Z. C., Thapa, R. K., Ou, W., Gautam, M., Nguyen, H. T., Jin, S. G., Ku, S., Oh, K. T., Choi, H., Yong, C. S., et al. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.07.013 · Cited by 99
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Schulte, R. R., & Ho, R. H. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.114314 · Cited by 98
Hatfield, M. J., Tsurkan, L. G., Garrett, M. R., Shaver, T. M., Hyatt, J. L., Edwards, C. C., Hicks, L. D., & Potter, P. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.09.001 · Cited by 95
Irinotecan-induced mucositis is associated with changes in intestinal mucins
Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., Laurence, J., & Keefe, D. M. K. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0855-y · Cited by 94
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32408 · Cited by 94
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
McKenzie, J. A., Mbofung, R. M., Malu, S., Zhang, M., Ashkin, E. L., Devi, S., Williams, L. J., Tieu, T. N., Peng, W., Pradeep, S., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx257 · Cited by 93
Glassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 92
Wu, Y., Wang, D., Yang, X., Fu, C., Zou, L., & Zhang, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.095 · Cited by 92
Interaction between Host Cells and Microbes in Chemotherapy-Induced Mucositis
Stringer, A. M. (2013) · Nutrients · doi:10.3390/nu5051488 · Cited by 91
Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0395 · Cited by 90
Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Swami, U., Goel, S., & Mani, S. (2013) · Current Drug Targets · doi:10.2174/1389450111314070007 · Cited by 88
Computational Approaches to Toll-Like Receptor 4 Modulation
Billod, J., Lacetera, A., Guzman‐Caldentey, J., & Martín‐Santamaría, S. (2016) · Molecules · doi:10.3390/molecules21080994 · Cited by 88
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 86
Iwai, T., Sugimoto, M., Wakita, D., Yorozu, K., Kurasawa, M., & Yamamoto, K. (2018) · Oncotarget · doi:10.18632/oncotarget.25830 · Cited by 82
Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin
Si, J., Zhao, X., Gao, S., Huang, D., & Sui, M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118499 · Cited by 76
Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy
Bala, V., Rao, S., Li, P., Wang, S., & Prestidge, C. A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00785 · Cited by 73
Pellock, S. J., Walton, W. G., Biernat, K. A., Torres-Rivera, D., Creekmore, B. C., Xu, Y., Liu, J., Tripathy, A., Stewart, L. J., & Redinbo, M. R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005414 · Cited by 73
Chiorean, E. G., Cheung, W. Y., Giordano, G., Kim, G., & Al-Batran, S. E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919850367 · Cited by 66
Mohammad, A. S., Griffith, J. I. G., Adkins, C. E., Shah, N., Sechrest, E. R., Dolan, E. L., Terrell-Hall, T. B., Hendriks, B. S., Lee, H., & Lockman, P. R. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2278-0 · Cited by 64
Park, S. J., Kim, Y. J., Kang, J. S., Kim, I. Y., Choi, K. S., & Kim, H. M. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02101 · Cited by 64
Immunological off-target effects of standard treatments in gastrointestinal cancers
Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 63
Martínez-Martínez, M., Rodríguez-Berna, G., Bermejo, M., González‐Álvarez, I., González‐Álvarez, M., & Merino, V. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.01.009 · Cited by 63
Li, N., Xu, H., Ou, Y., Feng, Z., Zhang, Q., Zhu, Q., & Cai, Z. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0780-x · Cited by 60
Lu, G., Rao, M., Zhu, P., Liang, B., El‐Nazer, R., Fonkem, E., Bhattacharjee, M. B., & Zhu, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00042 · Cited by 59
Hamaguchi, T., Tsuji, A., Yamaguchi, K., Takeda, K., Uetake, H., Esaki, T., Amagai, K., Sakai, D., Baba, H., Kimura, M., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3693-6 · Cited by 58
Bastos, R. W., Pedroso, S. H. S. P., Vieira, A. T., Moreira, L. M. C., Franca, C. S. L., Cartelle, C. T., Arantes, R. M. E., Generoso, S. V., Cardoso, V. N., Neves, M. J., et al. (2016) · Beneficial Microbes · doi:10.3920/bm2015.0190 · Cited by 55
Mabb, A. M., Simon, J. M., King, I. F. G., Lee, H.-M., An, L., Philpot, B. D., & Zylka, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156439 · Cited by 54
Shaojun, C., Li, H., Haixin, H., & Guisheng, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1414754 · Cited by 54
Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
Gilabert‐Oriol, R., Ryan, G. M., Leung, A. W. Y., Firmino, N. S., Bennewith, K. L., & Bally, M. B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102922 · Cited by 53
Herbal Medicines for Irinotecan-Induced Diarrhea
Tang, L., Li, X., Wan, L., Xiao, Y., Zeng, X., & Ding, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00182 · Cited by 53
Oyaga-Iriarte, E., Insausti, A., Sayar, O., & Aldaz, A. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.03.004 · Cited by 52
Palmerini, E., Jones, R. L., Setola, E., Picci, P., Marchesi, E., Luksch, R., Grignani, G., Cesari, M., Longhi, A., Abate, M. E., et al. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1449250 · Cited by 51
Hubner, R. A., Cubillo, A., Blanc, J., Melisi, D., Hoff, D. D. V., Wang‐Gillam, A., Chen, L., Becker, C., Mamlouk, K. K., Belanger, B., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.029 · Cited by 51
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Wagner, L. M. (2015) · Clinical Sarcoma Research · doi:10.1186/s13569-015-0035-x · Cited by 47
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma
Wang, L., Liang, L., Yang, T., Qiao, Y., Xia, Y., Liu, L., Li, C., Lu, P., & Jiang, X. (2017) · Medicine · doi:10.1097/md.0000000000009053 · Cited by 47
Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors
Ahmad, S., Hughes, M. A., Yeh, L.-A., & Scott, J. E. (2012) · SLAS Discovery · doi:10.1177/1087057112444927 · Cited by 44
Cheng, K.-W., Tseng, C.-H., Yang, C., Tzeng, C., Cheng, T.-C., Leu, Y.-L., Chuang, Y.-C., Wang, J., Lu, Y., Chen, Y.-L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00963 · Cited by 43
Kodawara, T., Higashi, T., Negoro, Y., Kamitani, Y., Igarashi, T., Watanabe, K., Tsukamoto, H., Yano, R., Masada, M., Iwasaki, H., et al. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12511 · Cited by 41
Sharkey, R. M., Govindan, S. V., Cardillo, T. M., Donnell, J., Xia, J., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0442 · Cited by 40
Alamgeer, M., Watkins, D. N., Banakh, I., Kumar, B., Gough, D. J., Markman, B., & Ganju, V. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0555-8 · Cited by 40
Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy197 · Cited by 38
Lam, W., Jiang, Z., Guan, F., Hu, R., Liu, S.-H., Chu, E., & Cheng, Y.-C. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-490 · Cited by 37
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
Fujii, H., Yamada, Y., Watanabe, D., Matsuhashi, N., Takahashi, T., Yoshida, K., & Suzuki, A. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3711-8 · Cited by 37
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
Wu, C., Zhang, Y., Yang, D., Zhang, J., Ma, J., Cheng, D., Chen, J., & Deng, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s187906 · Cited by 37
Harel, M., Hyatt, J. L., Brumshtein, B., Morton, C. L., Yoon, K. J. P., Wadkins, R. M., Silman, I., Sussman, J. L., & Potter, P. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009944 · Cited by 36
Bennett, R. P., Stewart, R. A., Hogan, P. A., Ptak, R. G., Mankowski, M. K., Hartman, T. L., Buckheit, R. W., Snyder, B. A., Salter, J. D., Morales, G. A., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.001 · Cited by 36
Deng, C., Deng, B., Jia, L., Tan, H., Zhang, P., Liu, S., Zhang, Y., Song, A., & Pan, L. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/7350251 · Cited by 35
Du, H., Huang, Y., Hou, X., Quan, X., Jiang, J., Wei, X., Liu, Y., Li, H., Wang, P., Zhan, M., et al. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.018 · Cited by 35
Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Wang, W., & Tse‐Dinh, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190401113350 · Cited by 35
Fatty liver and drugs: the two sides of the same coin.
Miele, L., Liguori, A., Marrone, G., Biolato, M., Araneo, C., Vaccaro, F. G., Gasbarrini, A., & Grieco, A. (2017) · PubMed · Cited by 34
Leonard, S. C., Lee, H., Gaddy, D. F., Klinz, S. G., Paz, N., Kalra, A. V., Drummond, D. C., Chan, D. C. F., Bunn, P. A., Fitzgerald, J. B., et al. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000545 · Cited by 34
Pan, P., Chen, J., Li, X., Li, M., Yu, H., Zhao, J. J., Ni, J., Wang, X., Sun, H., Tian, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00498 · Cited by 34
Thorpe, D. W., Butler, R. N., Sultani, M., Vanhoecke, B. W. A., & Stringer, A. M. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00644-x · Cited by 34
The clinical application of fruquintinib on colorectal cancer
Chen, Z., & Jiang, L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1630272 · Cited by 34
Desidero, T. D., Antonelli, A., Orlandi, P., Ferrari, S. M., Fioravanti, A., Alì, G., Fontanini, G., Basolo, F., Francia, G., & Bocci, G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.032 · Cited by 33
Prijovich, Z. M., Burnouf, P., Chou, H.-C., Huang, P.-T., Chen, K., Cheng, T., Leu, Y.-L., & Roffler, S. R. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00771 · Cited by 32
Wang, X., Cui, D.-N., Dai, X., Wang, J., Zhang, W., Zhang, Z., & Xu, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00156 · Cited by 32
Chemotherapy-induced gut toxicity and pain: involvement of TLRs
Gibson, R. J., Coller, J. K., Wardill, H. R., Hutchinson, M. R., Smid, S. D., & Bowen, J. M. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-3020-2 · Cited by 31
Dong, W., Shi, J., Yuan, T., Qi, B., Yu, J., Dai, J., & He, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.017 · Cited by 31
Adjuvant treatment of pancreatic cancer
Conroy, T., & Ducreux, M. P. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000546 · Cited by 31
Synthesis of uronic-Noeurostegine – a potent bacterial β-glucuronidase inhibitor
Rasmussen, T. S., Koldsø, H., Nakagawa, S., Kato, A., Schiøtt, B., & Jensen, H. H. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob06038d · Cited by 30
Li, F., Ling, X., Harris, D. L., Liao, J., Wang, Y., Westover, D., Jiang, G., Xu, B., Boland, P. M., & Jin, C. (2017) · Europe PMC (PubMed Central) · Cited by 30
Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan
Salvador‐Martín, S., García‐González, X., García, M. I., Blanco, C., Alfonso, P. G., Robles, L., Grávalos, C., Pachón, V., Longo, F., Martínez, V., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.026 · Cited by 30
New somatostatin-drug conjugates for effective targeting pancreatic cancer
Ragozin, E., Hesin, A., Bazylevich, A., Tuchinsky, H., Bovina, A., Zahavi, T. S., Oron‐Herman, M., Kostenich, G., Firer, M. A., Rubinek, T., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.032 · Cited by 29
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
Chen, M., Li, W., Zhang, X., Dong, Y., Hua, Y., Zhang, H., Gao, J., Zhao, L., Li, Y., & Zheng, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s133816 · Cited by 28
Enhanced Liver Targeting of Camptothecin via Conjugation with Deoxycholic Acid
Xiao, L., Yu, E., Yue, H., et al. (2019) · Molecules · doi:10.3390/molecules24061179 · Cited by 28
Hosseini, S. K., Kolterer, S., Steiner, M., von Manstein, V., Gerlach, K., Trojan, J., Waidmann, O., Zeuzem, S., Schulze, J. O., Hahn, S., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.003 · Cited by 27
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia
Hoang, V. T., Verma, D., Godavarthy, P. S., Llavona, P., Steiner, M., Gerlach, K., Michels, B. E., Bohnenberger, H., Wachter, A., Oellerich, T., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0358-8 · Cited by 27
Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Li, F. (2014) · PubMed · Cited by 26
Zhang, J. L., Sharma, P., Li, C. J., Dezube, B. J., Pardee, A. B., & Crumpacker, C. S. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.977 · Cited by 26
Bay, S. B., Kebudi, R., Görgün, Ö., Zülfikar, B., Darendeliler, E., & Çakır, F. B. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218790798 · Cited by 26
Woo, W., Carey, E. T., & Choi, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s167590 · Cited by 26
Macarulla, T. M., Blanc, J., Wang‐Gillam, A., Chen, L., Siveke, J. T., Mirakhur, B., Chen, J., & de Jong, F. A. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.02.011 · Cited by 26
Bernards, N., Ventura, M., Fricke, I. B., Hendriks, B. S., Fitzgerald, J. B., Lee, H., & Zheng, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00540 · Cited by 25
A novel mechanism of irinotecan targeting MDM2 and Bcl-xL
Lee, B., Min, J. A., Nashed, A., Lee, S.-O., Yoo, J. C., Chi, S., & Yi, G. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.009 · Cited by 25
Zhang, L. N., & Cui, H. (2018) · Nanotheranostics · doi:10.7150/ntno.25555 · Cited by 22
Monodisperse oligoethylene glycols modified Camptothecin, 10-Hydroxycamptothecin and SN38 prodrugs
Deng, T., Mao, X., Xiao, Y., Yang, Z., Zheng, X., & Jiang, Z. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.059 · Cited by 22
Wong, D. V. T., Filho, H. V. R., Wanderley, C. W. S., Leite, C. A., Lima, J. B., Assef, A. N. B., Cajado, A. G., Batista, G. D. O., González, R. H., Silva, K. O., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03844-z · Cited by 21
Hamano, H., Mitsui, M., Zamami, Y., Takechi, K., Nimura, T., Okada, N., Fukushima, K., Imanishi, M., Chuma, M., Horinouchi, Y., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4367-y · Cited by 20
Iwase, M., Fujita, K., Nishimura, Y., Seba, N., Masuo, Y., Ishida, H., Kato, Y., & Kiuchi, Y. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03784-8 · Cited by 18
A series of camptothecin prodrugs exhibit HDAC inhibition activity
Zhu, Q., Yu, X., Shen, Q., Zhang, Q., Su, M., Zhou, Y., Li, J. X., Chen, Y., & Lu, W. P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.008 · Cited by 17
Cheng, C., Lau, J., & Earl, M. A. (2015) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0099 · Cited by 16
Kimura, K., Yamano, T., Igeta, M., Imada, A., Jihyung, S., Babaya, A., Hamanaka, M., Kobayashi, M., Tsukamoto, K., Noda, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13807 · Cited by 16
Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo
Zhang, X., Zhang, G., Ren, Y., Lan, T., Li, D., Tian, J., & Jiang, W. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.044 · Cited by 14
Kanbayashi, Y., Ishikawa, T., Kanazawa, M., Nakajima, Y., Tabuchi, Y., Kawano, R., Yoshioka, T., Yoshida, N., Hosokawa, T., Takayama, K., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1142-3 · Cited by 13
Liang, D., Wu, X., Hasinoff, B. B., Herbert, D. E., & Tranmer, G. K. (2018) · Molecules · doi:10.3390/molecules23082041 · Cited by 13
Bosch, L. J. W., Trooskens, G., Snæbjörnsson, P., Coupé, V. M. H., Mongera, S., Haan, J. C., Richman, S. D., Koopman, M., Tol, J., Meyer, T. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18702 · Cited by 12
Desjardins, A., Herndon, J. E., McSherry, F., Ravelo, A., Lipp, E., Healy, P. N., Peters, K. B., Sampson, J. H., Randazzo, D. M., Sommer, N., et al. (2019) · Health Science Reports · doi:10.1002/hsr2.114 · Cited by 12
Fakiha, K. G., Coller, J. K., Logan, R. M., Gibson, R. J., & Bowen, J. M. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4511-8 · Cited by 11
Xu, J. H., Xie, L., Sun, X., Dong, S., Tang, X., & Guo, W. (2019) · Oncology Letters · doi:10.3892/ol.2019.10328 · Cited by 10
Sy, S. K. B., Sweeney, T. D., Ji, C., Hoch, U., & Eldon, M. A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3192-6 · Cited by 7
Development of New ADC Technology with Topoisomerase I Inhibitor
Agatsuma, T. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.16-00255-4 · Cited by 7
Vision loss after chemotherapy: an irinotecan-induced retinopathy
Boilève, A., Jozwiak, M., Malka, D., Boige, V., Roy, F. L., Pâques, M., & Ducreux, M. P. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.02.015 · Cited by 6
Yamada, Y., Fujii, H., Ohata, K., Kato‐Hayashi, H., Watanabe, D., Ishihara, T., Uemura, S., Iwashita, T., Imai, H., Matsuhashi, N., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1288-7 · Cited by 6
Nanocrystals of a new camptothecin derivative WCN-21 enhance its solubility and efficacy
You, J., Chen, Y., Alsayeh, Z. M., Shen, X., Li, C., Zhao, P., Chen, F., Liu, Y., & Xu, C. (2017) · Oncotarget · doi:10.18632/oncotarget.16159 · Cited by 5
CT‑1042, a novel anticancer agent, exhibits effects by activating p53 and inhibiting survivin
Yang, J., Li, L., Xu, C., Yang, D., Wang, S., & Yuan, S. (2018) · Oncology Reports · doi:10.3892/or.2018.6354 · Cited by 5
Kümler, I., Balslev, E., Stenvang, J., Brünner, N., Ejlertsen, B., Jakobsen, E. H., & Nielsen, D. L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5788-9 · Cited by 5
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020299 · Cited by 363
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Metadata
- Authors
- Bailly, C.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 148
- Pages
- 104398
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2966911669
- Cited by
- 456
- References
- 128
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.